Illumina
ILMN
$177.65
+1.46%
Illumina Inc. is a global leader in genomic sequencing and array-based technologies, providing essential tools and services for analyzing genetic material across life science research and clinical diagnostics. The company holds a dominant market position as the primary provider of high-throughput sequencing instruments and consumables, which generate over 90% of its revenue, effectively making it the infrastructure backbone for the genomics industry. The current investor narrative is intensely focused on the company's post-spin-off trajectory following the divestiture of Grail, with debates centering on whether Illumina can return to core revenue growth and margin expansion in its sequencing business amid a challenging macroeconomic environment for life science tools.…
ILMN
Illumina
$177.65
Related headlines
Investment Opinion: Should I buy ILMN Today?
Rating & Thesis: Hold. Illumina is a high-quality company in a powerful uptrend, but its premium valuation and modest growth profile create a balanced risk/reward at current levels, aligning with the mixed but cautiously optimistic analyst sentiment.
Supporting Evidence: The stock trades at a forward P/E of 27.33x, a premium to its sector, justified by its 66.69% gross margin and 31.22% ROE. Revenue growth, while positive at 4.98% YoY, remains modest. The company generates strong free cash flow ($939M TTM) and has returned to profitability with a Q4 net margin of 28.82%. The technical picture is bullish with a 79.40% one-year gain, but this strong performance is already reflected in the price.
Risks & Conditions: The two biggest risks are valuation compression if growth disappoints and high volatility (beta 1.49) during market stress. This Hold rating would upgrade to a Buy if the forward P/E compresses below 22x on sustained earnings growth, or if quarterly revenue growth accelerates sustainably above 8%. It would downgrade to a Sell if revenue growth turns negative or if the stock breaks below key technical support at $140. Currently, the stock is fairly valued relative to its own high-quality fundamentals but overvalued relative to sector peers, pricing in a near-perfect execution of its recovery narrative.
Sign up to view all
ILMN 12-Month Price Forecast
Illumina presents a classic 'high-quality at a fair price' scenario. The company's fundamentals are robust, with industry-leading margins and a clear path to stable profitability. However, the stock's dramatic 79% rally over the past year and its premium valuation have largely priced in this recovery, leaving limited near-term upside without an acceleration in growth. The neutral stance reflects this balance. The stance would upgrade to bullish on evidence of sustained revenue growth acceleration above 7% or a pullback that offers a better entry point below a 25x forward P/E. It would turn bearish if growth stalls or margins begin to contract, validating valuation concerns.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Illumina's 12-month outlook, with a consensus price target around $230.95 and implied upside of +30.0% versus the current price.
Average Target
$230.95
10 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
10
covering this stock
Price Range
$142 - $231
Analyst target range
Analyst coverage for Illumina is substantial, with 10 firms providing estimates, indicating strong institutional interest. The consensus sentiment appears mixed but leans cautiously optimistic, with recent institutional ratings including 'Buy' from Guggenheim and Stifel, 'Hold' from Canaccord Genuity and TD Cowen, and 'Underweight' from Barclays. The average revenue estimate for the coming period is $5.83 billion, with a tight range between $5.77 billion and $5.90 billion, suggesting high conviction in the near-term revenue trajectory. The average EPS estimate is $8.84, with a narrow band from $8.72 to $8.98. While a specific consensus price target is not provided in the data, the tight estimate ranges and the prevalence of 'Buy' and 'Hold' ratings in recent months point to a stabilization in analyst views following the Grail spin-off. The wide dispersion in ratings—from Underweight to Buy—signals ongoing debate about the pace of the core business recovery and the sustainability of current margins, leading to higher uncertainty and potential stock volatility.
Bulls vs Bears: ILMN Investment Factors
The bull case, currently supported by stronger evidence, is anchored in Illumina's exceptional profitability metrics, powerful technical momentum, and its return to core growth post-Grail. The bear case centers on the stock's premium valuation, modest growth rate, and high volatility. The single most important tension in the investment debate is whether Illumina's dominant market position and high margins can sustainably support its premium valuation in the face of only low-single-digit revenue growth. The resolution of this growth-versus-valuation conundrum will determine the stock's direction.
Bullish
- Exceptional Profitability & Strong Margins: Illumina's Q4 net margin of 28.82% and trailing gross margin of 66.69% demonstrate superior pricing power and operational efficiency. The company's return on equity of 31.22% is exceptionally strong, indicating highly efficient use of shareholder capital.
- Powerful Technical Uptrend & Momentum: The stock has gained 79.40% over the past year and 30.24% over three months, significantly outperforming the SPY. Trading at 91% of its 52-week high ($177.22), the price action shows strong momentum and a clear uptrend.
- Robust Free Cash Flow Generation: The company generated $939 million in trailing twelve-month free cash flow, providing ample internal funding for growth initiatives and potential shareholder returns. This strong cash flow underpins financial stability and strategic flexibility.
- Return to Core Growth & Profitability: Q4 revenue grew 4.98% YoY to $1.159 billion, marking a steady sequential recovery. More importantly, the company returned to strong profitability with Q4 net income of $334 million, signaling a successful post-Grail restructuring.
Bearish
- Premium Valuation Relative to Sector: With a trailing P/E of 24.52x and a forward P/E of 27.33x, Illumina trades at a significant premium to its Medical Diagnostics & Research industry peers. This high multiple raises the bar for flawless execution and leaves little room for disappointment.
- Modest Revenue Growth Trajectory: Despite the recovery, Q4 revenue growth of 4.98% remains in the low single digits. For a stock priced for growth, this modest pace may struggle to justify its elevated valuation multiples over the long term.
- High Beta & Elevated Volatility Risk: The stock's beta of 1.49 indicates it is approximately 50% more volatile than the broader market. This high volatility, evidenced by a recent 52-week low of $88.00, poses significant risk for investors during market downturns.
- Analyst Sentiment Remains Mixed: Recent institutional ratings range from 'Underweight' (Barclays) to 'Buy' (Guggenheim, Stifel), reflecting ongoing debate about the sustainability of the recovery. This lack of consensus contributes to uncertainty and potential stock price volatility.
ILMN Technical Analysis
The stock is in a powerful, sustained uptrend, evidenced by a 79.40% gain over the past year. As of the latest close of $161.93, the price is trading at approximately 91% of its 52-week high of $177.22, indicating strong momentum but also positioning it near a critical resistance level where profit-taking or overextension concerns may arise. The stock has significantly outperformed the broader market, with a relative strength of 54.41% versus the SPY over the same period. Recent momentum shows acceleration, with a 14.29% gain over the past month and a 30.24% gain over three months, both substantially outpacing the SPY's returns of 0.74% and 15.14%, respectively. This suggests the bullish trend is not only intact but gaining strength, though the sharp rally from the February low of $114.44 warrants caution for a potential near-term consolidation. Key technical levels are clearly defined, with major resistance at the 52-week high of $177.22 and support at the 52-week low of $88.00. A decisive breakout above $177.22 would signal a continuation of the bullish trend, while a failure could lead to a retest of the $140-$150 consolidation zone. The stock's beta of 1.49 indicates it is approximately 50% more volatile than the market, which is critical for risk management as it implies larger swings in both directions.
Beta
1.49
1.49x market volatility
Max Drawdown
-25.7%
Largest decline past year
52-Week Range
$88-$183
Price range past year
Annual Return
+90.6%
Cumulative gain past year
| Period | ILMN Return | S&P 500 |
|---|---|---|
| 1m | +22.3% | -2.2% |
| 3m | +51.0% | +15.8% |
| 6m | +31.6% | +6.4% |
| 1y | +90.6% | +20.9% |
| ytd | +32.2% | +7.7% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
ILMN Fundamental Analysis
Revenue growth has been modest but positive, with Q4 2025 revenue of $1.159 billion representing a 4.98% year-over-year increase. The multi-quarter trend shows sequential revenue growth from $1.041 billion in Q1 to $1.159 billion in Q4, indicating a steady recovery, though growth remains in the low single digits. The business is heavily driven by the Sequencing segment, which contributed $1.065 billion (92%) of total revenue in the latest period, while the Microarray segment contributed $94 million (8%). The company has returned to profitability with a strong Q4, reporting net income of $334 million and a net margin of 28.82%. Gross margins are robust at 67.04% for the quarter, consistent with the trailing gross margin of 66.69%, reflecting the company's pricing power and efficient manufacturing. Operating income of $256 million and an operating margin of 22.09% demonstrate solid operational execution following a period of restructuring. The balance sheet and cash flow position are healthy, with a current ratio of 2.08 indicating strong short-term liquidity. The company generated $939 million in trailing twelve-month free cash flow, providing ample internal funding for growth and shareholder returns. The debt-to-equity ratio of 0.94 is manageable, and a return on equity of 31.22% is exceptionally strong, signaling efficient use of shareholder capital.
Quarterly Revenue
$1.2B
2025-12
Revenue YoY Growth
+0.04%
YoY Comparison
Gross Margin
+0.67%
Latest Quarter
Free Cash Flow
$939000000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is ILMN Overvalued?
Given the positive net income of $334 million in the latest quarter, the primary valuation metric is the P/E ratio. The trailing P/E is 24.52x, while the forward P/E is 27.33x based on estimated EPS of $8.84; the higher forward multiple suggests the market is pricing in expectations for earnings growth in the coming year. Compared to sector averages, Illumina trades at a significant premium; its trailing P/E of 24.52x and Price/Sales ratio of 4.81x are elevated for the Medical Diagnostics & Research industry, which typically features lower multiples due to growth normalization post-pandemic. This premium is likely justified by the company's market dominance, high gross margins of 66.69%, and its critical role as a genomic platform, but it also raises the bar for execution. Historically, the stock's current trailing P/E of 24.52x sits well below its own peak historical multiples seen in 2021 (over 90x) but is above the depressed levels seen during its Grail-related struggles in 2023-2024. This positioning suggests the market has repriced the stock for a stable, profitable growth story rather than the hyper-growth or significant uncertainty narratives of the past.
PE
24.5x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range -56x~2943x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
15.1x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Illumina's primary financial risk is its premium valuation, with a forward P/E of 27.33x demanding consistent earnings growth. While the balance sheet is healthy with a manageable debt-to-equity ratio of 0.94, the company's heavy revenue concentration in the Sequencing segment (92%) creates operational vulnerability. Any slowdown in capital expenditure by life science research customers, a key end-market, could immediately pressure the low single-digit growth trajectory and compress margins from their current robust levels (28.82% net margin).
Market & Competitive Risks: The stock's high beta of 1.49 makes it highly sensitive to broader market swings and sector rotations, particularly away from growth stocks. Trading at a Price/Sales ratio of 4.81x, which is elevated for its industry, the stock faces valuation compression risk if interest rates remain elevated or growth expectations falter. While its technological moat is strong, the long-term risk of disruptive, lower-cost sequencing technologies emerging cannot be ignored, though it is not an immediate threat.
Worst-Case Scenario: The most damaging scenario would involve a combination of a broader market correction impacting high-beta stocks and a company-specific earnings miss that shatters the narrative of a steady recovery. This could trigger multiple analyst downgrades from the current mixed sentiment and lead to a rapid de-rating. A realistic downside could see the stock re-test its 52-week low of $88.00, representing a potential loss of approximately -46% from the current price of $161.93, especially if quarterly revenue growth decelerates or turns negative.
FAQ
The key risks are, in order of severity: 1) Valuation Risk: The premium forward P/E (27.33x) could compress sharply if growth decelerates. 2) Volatility Risk: The high beta of 1.49 means the stock will likely fall more than the market during downturns, as seen in its 52-week low of $88. 3) Operational Concentration: Over 90% of revenue comes from the Sequencing segment, creating vulnerability to any disruption in that single market. 4) Growth Sustainability: Current low-single-digit revenue growth may not be sufficient to justify the premium multiple over the long term.
The 12-month outlook presents three scenarios. The Base Case (50% probability) sees the stock trading between $155 and $180, assuming steady execution and maintained valuation. The Bull Case (30% probability) targets $185 to $210, driven by accelerated growth and multiple expansion. The Bear Case (20% probability) warns of a drop to $100-$135 if growth stalls amid a market downturn. The Base Case is most likely, predicated on the company delivering consistent, low-single-digit growth and strong profitability without major surprises.
ILMN is fairly valued relative to its own high-quality fundamentals but trades at a premium relative to its sector. Its forward P/E of 27.33x and Price/Sales of 4.81x are elevated for the Medical Diagnostics & Research industry. This premium is justified by its 66.69% gross margin, 31.22% ROE, and market dominance, but it also implies the market expects steady execution and sustained profitability. The valuation is not egregious given the company's quality, but it leaves little margin for error, making the stock susceptible to de-rating if growth disappoints.
ILMN is a good buy for investors seeking a high-quality, dominant company in the genomics space, but timing is crucial. At its current price near the 52-week high and a forward P/E of 27.33x, much of the post-Grail recovery is already priced in. The stock offers a compelling long-term hold for those who believe in the secular growth of genomics and can tolerate its high volatility (beta 1.49). For new money, a better strategy might be to wait for a pullback or for evidence that revenue growth is accelerating beyond the current ~5% pace.
ILMN is more suitable for a long-term investment horizon of 3-5 years. While the stock exhibits high short-term volatility (beta 1.49) that could appeal to traders, its value proposition is as a long-term compounder benefiting from the growth of genomic data. The company pays no dividend, directing cash flow to reinvestment, which aligns with a growth-oriented, long-term holding. Short-term traders must be prepared to manage the significant price swings evidenced by its 52-week range of $88 to $177.22.